Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CleveXel Pharma Partners with Dynamix Pharmaceuticals

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
CleveXel and Dynamix to develop a dual mechanism SYK/JAK small molecule inhibitor to clinical proof-of-concept.

Clevexel Pharma has announced that they have entered into a partnering agreement with Dynamix Pharmaceuticals, a venture-backed Israeli biopharmaceutical company focused on the discovery and development of novel, targeted, small-molecule drugs for cancer and autoimmune disorders.

The partnership will cover the development of a dual mechanism SYK/JAK molecule in rheumatoid arthritis. The orally active SYK/JAK product has a new action and is Dynamix’ lead development program.

Over the past decade, efforts have been made to provide an oral treatment for rheumatoid arthritis (RA) with the desired efficacy and safety profile. Oral administration is of great interest as current treatments are mainly only injectable.

The joint aim of the collaboration between CleveXel and Dynamix is to bring the rheumatoid arthritis project to a clinical proof of concept stage. Preclinical development is planned for early 2014. The first in human clinical trial is expected to start in 2015.

Rheumatoid arthritis is a chronic and debilitating autoimmune disease of unknown etiology. It is linked to significant morbidity. The associated inflammatory processes cause the destruction of cartilage and bone, leading to joint swelling, pain and, ultimately, joint destruction.

Over the next few years, the global rheumatoid arthritis market is expected to grow from USD 18.6 billion in 2012 to USD 26.0 billion in 2017 (FirstWord, June 2013).

Rheumatoid arthritis affects 1.3 million Americans and 2.9 million Europeans (Arthritis Foundation) (Abbott). Patients are currently mainly treated with anti-TNF monoclonal antibodies therapies.

“We are happy to collaborate with CleveXel and to gain access to their development expertise”, said Batsheva Elran, managing partner at Opal Ventures and chairman of Dynamix. “This collaboration is an excellent opportunity to share the risks in developing an innovative project in inflammatory diseases and to address unmet needs,” said Dr Itzchak Angel, CEO of Angel Pharmaceutical Consulting and Technologies, who represent Dynamix Pharmaceuticals in this partnership.

“For CleveXel, the partnership will innovate in inflammatory disease, potentially also in oncology,” said Christian Bloy, CEO of CleveXel. “JAK3 and SYK represent new targets that are extremely interesting in order to develop an orally administered product. CleveXel Pharma is very happy to be part of this leading project with Dynamix.”

This new agreement will strengthen CleveXel’s product portfolio both in financial and non-monetary asset investments. This is the fourth molecule in CleveXel’s portfolio since the beginning of 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!